ObjectiveTo observe the efficacy and safety of thalidomide + dexamethasone (TD) regimen combined with bortezomib in the treatment of patients with multiple myeloma (MM). MethodsA total of 86 MM patients admitted to our hospital from April 2018 to April 2020 were enrolled, and they were randomly divided into observation group and control group, with 43 cases in each group. The control group was treated with TD regimen, while the observation group was treated with TD regimen combined with bortezomib, with 28 days as a cycle of treatment and 3 treatment cycles for both groups. The total effective rate was compared between the two groups. The human Dickkopf-1 (DKK-1) gene, osteoprotegerin (OPG), vascular endothelial growth factor (VEGF), and interleukin (IL)-6 and IL-17 levels were detected and compared between the two groups. The occurrence of adverse reactions during the treatment was compared between the two groups. ResultsAfter 3 cycles of treatment, the total effective rate of the observation group (88.4%) was significantly higher than that of the control group (69.8%), with a statistically significant difference (P＜0.05). After 3 cycles of treatment, the serum DKK-1 levels of the two groups significantly decreased, and the observation group yielded lower level in comparison with the control group; the OPG levels of the two groups significantly increased, and the observation group yielded higher level in comparison with the control group. The serum VEGF, IL-6, and IL-17 levels of the two groups significantly decreased, while the observation group yielded lower levels in comparison with the control group, with statistically significant differences (P＜0.05). During the treatment period, there was no statistically significant difference in the incidence of adverse reactions between the two groups (P＞0.05). ConclusionTD regimen combined with bortezomib in treating MM patients has a prominently clinical efficacy. It can significantly improve bone metabolism, and reduce inflammation response, with high safety.

无